Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
26.80
+0.09 (0.34%)
Market open: Aug 12, 2026, 11:05 AM EDT
26.40
-0.31 (-1.16%)
Previous after-hours: Aug 11, 2026, 7:56 PM EDT
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations |
| Dr. Douglas Kerr M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Innovation Officer |
| Dr. Rajesh Manchanda Ph.D. | Chief Technical Officer |
| Mr. Alessandro Martuscelli | Chief Legal Officer |
| Mr. Erick J. Lucera C.F.A., CPA | CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer |
| Mr. James P. Bilotta M.B.A. | Chief Digital & Information Officer |
| Mr. John G. Cox M.B.A. | CEO, President & Director |
| Ms. Johanna Friedl-Naderer | Chief Commercial Officer |
| Ms. Lucia Celona | Chief Human Resource Officer |
| Date | Type | Document |
|---|---|---|
| 2026-07-29 | 8-K | dyn-20260729.htm |
| 2026-07-20 | 8-K | dyn-20260720.htm |
| 2026-06-22 | 8-K | dyn-20260622.htm |
| 2026-06-17 | 8-K | dyn-20260616.htm |
| 2026-06-08 | 8-K | dyn-20260605.htm |
| 2026-06-03 | 8-K | dyn-20260603.htm |
| 2026-05-11 | 8-K | dyn-20260511.htm |
| 2026-05-11 | 10-Q | dyn-20260331.htm |
| 2026-04-23 | DEFA14A | 2026_proxy_notice.htm |
| 2026-04-23 | DEF 14A | dyn-20260422.htm |